Rheumatology

Medicine & Life Sciences

1. Rheumatology 100%
2. Juvenile Arthritis 78%
3. Systemic Lupus Erythematosus 70%
4. Arthritis 66%
5. Registries 48%
6. Pediatrics 40%
7. Lupus Nephritis 23%
8. Child 20%
9. Transition to Adult Care 20%
10. Dermatomyositis 18%
11. Granulomatosis with Polyangiitis 17%
12. Antirheumatic Agents 16%
13. Patient Reported Outcome Measures 15%
14. Young Adult 15%
15. Rheumatologists 14%
16. Biological Products 13%
17. Vasculitis 12%
18. Myositis 12%
19. Therapeutics 12%
20. Interferon Type I 11%
21. Cohort Studies 10%
22. Sacroiliitis 10%
23. Dendritic Cells 10%
24. Microscopic Polyangiitis 9%
25. Consensus 9%
26. Arthropathy, progressive pseudorheumatoid, of childhood 9%
27. Nephritis 9%
28. Glucocorticoids 8%
29. Kidney 8%
30. Safety-net Providers 8%
31. Antineutrophil Cytoplasmic Antibodies 8%
32. Observational Studies 7%
33. Poverty 7%
34. Social Determinants of Health 7%
35. B-Lymphocytes 7%
36. Nucleic Acids 7%
37. Etanercept 6%
38. Patient Acceptance of Health Care 6%
39. Localized Scleroderma 6%
40. Information Systems 6%
41. Muscles 6%
42. Translational Medical Research 6%
43. Interferons 6%
44. Recreation 6%
45. Uveitis 6%
46. B-Lymphocyte Subsets 5%
47. Antiphospholipid Antibodies 5%
48. Interviews 5%
49. Health Literacy 5%
50. Connective Tissue Diseases 5%
51. Succinic Acid 5%
52. Joints 5%
53. Patient Care Team 5%
54. Antibodies 5%
55. Population 5%
56. Psychology Transfer 5%
57. Education 5%
58. Methotrexate 5%
59. Patient Participation 5%
60. Neutrophils 5%
61. Autoantibodies 5%
62. Steroids 5%